239000005557 antagonist Substances 0.000 claims description 55.150000001875 compounds Chemical class 0.000 claims description 67.150000001413 amino acids Chemical class 0.000 claims description 104.230000014509 gene expression Effects 0.000 claims description 167.229920001405 Coding region Polymers 0.000 claims abstract description 41.108020004707 nucleic acids Proteins 0.000 claims abstract description 85.239000002299 complementary DNA Substances 0.000 claims abstract description 95.229920002676 Complementary DNA Polymers 0.000 claims abstract description 102.150000007523 nucleic acids Chemical class 0.000 claims abstract description 138.229920003013 deoxyribonucleic acid Polymers 0.000 claims abstract description 138.125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 152.229920001184 polypeptide Polymers 0.000 claims abstract description 588.108040001304 interleukin-17 receptor activity proteins Proteins 0.000 title 1.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority to US17209699P priority Critical Priority to US172096P priority Priority to WOUS99/31274 priority Priority to PCT/US1999/031274 priority patent/WO2000053752A2/en Priority to US17548100P priority Priority to US175481P priority Priority to PCT/US2000/004341 priority patent/WO2000053756A2/en Priority to WOUS00/04341 priority Priority to WOUS00/05841 priority Priority to PCT/US2000/007532 priority patent/WO2000070050A1/en Priority to US191007P priority Priority to US19100700P priority Priority to WOUS00/07532 priority Priority to PCT/US2000/015264 priority patent/WO2000073452A2/en Priority to WOUS00/15264 priority Priority to US21380700P priority Priority to US213807P priority Priority to US64484800A priority Priority to US644848 priority Priority to WOUS00/23328 priority Priority to PCT/US2000/023328 priority patent/WO2001016318A2/en Priority to US24283700P priority Priority to US242837P priority Priority to PCT/US2000/030873 priority patent/WO2001040465A2/en Priority to WOUS00/30873 priority Priority to US25364600P priority Priority to US253646P priority Priority to WOUS00/32678 priority Application filed by Genentech Inc filed Critical Genentech Inc Application granted granted Critical Publication of ES2333772T3 publication Critical patent/ES2333772T3/en Anticipated expiration legal-status Critical Status Expired - Lifetime legal-status Critical Current Links Original Assignee Genentech Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Yansura Current Assignee (The listed assignees may be inaccurate. Hillan Daniel Tumas Menno Van Lookeren Richard L.
Inventor Jian Chen Ellen Filvaroff Sherman Fong Audrey Goddard Paul J.
Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired - Lifetime Application number ES00989401T Other languages Spanish ( es)
Translate pro z se encuentra el paciente pdf#
HOMOLOGICAL POLIPEPTIDES OF IL-17 AND IL-17R AND THEIR THERAPEUTIC USESĭownload PDF Info Publication number ES2333772T3 ES2333772T3 ES00989401T ES00989401T ES2333772T3 ES 2333772 T3 ES2333772 T3 ES 2333772T3 ES 00989401 T ES00989401 T ES 00989401T ES 00989401 T ES00989401 T ES 00989401T ES 2333772 T3 ES2333772 T3 ES 2333772T3 Authority ES Spain Prior art keywords polypeptide cell pro10272 amino acid acid sequence Prior art date Legal status (The legal status is an assumption and is not a legal conclusion.
0 kommentar(er)
